Association of Adjuvant or Metastatic Setting With Discontinuation of Cancer Drugs in Clinical Trials-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Association of Adjuvant or Metastatic Setting With Discontinuation of Cancer Drugs in Clinical Trials

Published:2022-05-16 Issue:5 Volume:5 Page:e2212327
ISSN:2574-3805
Container-title:JAMA Network Open
language:en
Short-container-title:JAMA Netw Open

Author:

Ahmed Nibras¹,Vengalasetti Yasaswi²,Haslam Alyson³,Prasad Vinay³⁴

Affiliation:

1. Department of Biological Sciences, City University of New York, Hunter College, New York City

2. Department of Epidemiology and Population Health, Stanford University School of Medicine, Stanford, California

3. Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco

4. Department of Medicine, University of California, San Francisco, San Francisco

Publisher

American Medical Association (AMA)

Subject

General Medicine

Link

https://jamanetwork.com/journals/jamanetworkopen/articlepdf/2792366/ahmed_2022_oi_220363_1651903696.18437.pdf

Reference18 articles.

1. Comparison of drugs used for adjuvant and metastatic therapy of colon, breast, and non-small cell lung cancers.;Parsons;JAMA Netw Open,2020

2. Characteristics of preapproval and postapproval studies for drugs granted accelerated approval by the US Food and Drug Administration.;Naci;JAMA,2017

3. Making adjuvant therapy decisions with uncertain data.;Gyawali;Ann Oncol,2019

4. Retrieving clinical evidence: a comparison of PubMed and Google Scholar for quick clinical searches.;Shariff;J Med Internet Res,2013

5. Development and economic trends in anticancer drugs licensed in the UK from 2015 to 2019.;Lythgoe;Drug Discov Today,2021

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cost of Drug Wastage From Dose Modification and Discontinuation of Oral Anticancer Drugs;JAMA Oncology;2023-09-01

2. Rationale and trial design of NATALEE: a Phase III trial of adjuvant ribociclib + endocrine therapy versus endocrine therapy alone in patients with HR+/HER2− early breast cancer;Therapeutic Advances in Medical Oncology;2023-01

3. Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB–IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial;The Lancet Oncology;2022-10

4. Collagen Remodeling along Cancer Progression Providing a Novel Opportunity for Cancer Diagnosis and Treatment;International Journal of Molecular Sciences;2022-09-10

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3